Medicilon(688202)2025-01-17 11:00Financial Performance Expectations - The company expects a net loss attributable to shareholders for 2024 to be between -347 million and -232 million RMB, a decrease of 198.79 million to 313.79 million RMB compared to the previous year [2]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is projected to be between -367 million and -245 million RMB, a decrease of 187.38 million to 309.38 million RMB compared to the previous year [5]. - The total profit for the previous year was -59.11 million RMB, with a net profit attributable to shareholders of -33.21 million RMB [7]. - The company reported a basic earnings per share of -0.26 RMB for the previous year [8]. Factors Affecting Profitability - The decline in net profit is primarily due to a slowdown in investment and financing in the pharmaceutical industry, leading to a significant change in market demand and intensified competition [9]. - The company has implemented strict cost control measures, but it has been challenging to adjust costs in line with the revenue decline in the short term [9]. - The company has recognized impairment losses or provisions for receivables, long-term assets, inventory, and contract orders, which have negatively impacted the current net profit [9]. Forecast and Risk Advisory - The performance forecast has not been audited by a registered accountant and is based on preliminary calculations by the finance department [10]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and the final audited financial data will be disclosed in the 2024 annual report [11].